Minocycline Treatment for Cystoid Macular Edema
MINOCME
Efficacy and Safety of the Treatment of Minocycline for Cystoid Macular Edema
1 other identifier
interventional
5
1 country
1
Brief Summary
Cystoid macular edema (CME) is one of sight-threatening, immune-related ocular diseases. The efficacy of current treatments for CME (anti-VEGF, glucocorticoids and other agents) are limiting. Minocycline, acting as a broad-spectrum antibiotic, is among tetracycline family and recently, its immunomodulatory and anti-apoptosis function has been replied to several immune diseases and degenerative diseases. This study aims to explore the efficacy and safety of minocycline for CME.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for phase_1
Started Jan 2019
Longer than P75 for phase_1
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 1, 2019
CompletedFirst Submitted
Initial submission to the registry
July 23, 2022
CompletedFirst Posted
Study publicly available on registry
July 26, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 1, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 1, 2025
CompletedApril 19, 2023
April 1, 2023
5.4 years
July 23, 2022
April 16, 2023
Conditions
Outcome Measures
Primary Outcomes (1)
Change of cystoid macular edema
Change of CME measured by Optical coherence tomography (OCT)
At 6 months
Secondary Outcomes (4)
Change of best corrected visual acuity (BCVA)
At 6 months
Change of macular sensitivity
At 6 months
Change of retinal vascular leakage
At 6 months
Change of macular vessel
At 6 months
Study Arms (1)
minocycline
EXPERIMENTALInterventions
Eligibility Criteria
You may qualify if:
- Participant diagnosed with CME.
- Participant aged from 18-60 years old.
- Participant that signed the informed consent document and is able to complete the following visits.
You may not qualify if:
- Participant is allergy to minocycline or tetracyclines.
- Participant has no contraindications of minocycline or tetracyclines.
- Participant has an abnormal function of liver, heart, kidney and thyroid.
- Female that is pregnant, breast-feeding or planning to become pregnant.
- Participant that is currently using other medications.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Zhongshan Ophthalmic Center
Guangzhou, Guangdong, 510000, China
Related Publications (1)
Romano F, Lamanna F, Gabrielle PH, Teo KYC, Battaglia Parodi M, Iacono P, Fraser-Bell S, Cornish EE, Nassisi M, Viola F, Agarwal A, Samanta A, Chhablani J, Staurenghi G, Invernizzi A. Update on Retinal Vein Occlusion. Asia Pac J Ophthalmol (Phila). 2023 Mar-Apr 01;12(2):196-210. doi: 10.1097/APO.0000000000000598. Epub 2023 Feb 14.
PMID: 36912792DERIVED
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- interventional
- Phase
- phase 1
- Allocation
- NA
- Masking
- NONE
- Purpose
- TREATMENT
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dan Liang, PhD
Study Record Dates
First Submitted
July 23, 2022
First Posted
July 26, 2022
Study Start
January 1, 2019
Primary Completion
June 1, 2024
Study Completion
June 1, 2025
Last Updated
April 19, 2023
Record last verified: 2023-04